Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients.
Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients.
复制标题
马沙骨化醇治疗尿毒症患者继发性甲状旁腺功能亢进症的临床效果
DOI：
--
复制
发表时间：
2001
影响因子：
13.2
通讯作者：
K. Kurokawa
中科院分区：
文献类型：
--
作者：
T. Akizawa;M. Suzuki;T. Akiba;Y. Nishizawà;K. Kurokawa
Maxacalcitol（22-oxacalcitriol [OCT]）是日本新开发的维生素D类似物。OCT在尿毒症大鼠和犬中显示出较少的钙化作用和对甲状旁腺激素（PTH）的强烈抑制作用。在继发性甲状旁腺功能亢进的尿毒症患者中，OCT剂量依赖性地抑制PTH分泌并增加血清钙水平。然而，超过60%的患者在长达1年的长期OCT治疗中实现了完整PTH水平较基线降低30%以上，而平均血清钙水平未出现非生理性升高。长期治疗还导致骨代谢标志物的减少，包括骨碱性磷酸酶、抗酒石酸酸性磷酸酶和骨革兰氏蛋白。这些结果表明，虽然应特别注意高钙血症和PTH的过度抑制的发病，OCT是治疗继发性甲状旁腺功能亢进的有效工具之一。
Maxacalcitol (22-oxacalcitriol [OCT]) is a newly developed vitamin D analogue in Japan. OCT has shown less calcemic action and a strong suppressive effect on parathyroid hormone (PTH) in uremic rats and dogs. In uremic patients with secondary hyperparathyroidism, OCT dose-dependently suppressed PTH secretion and increased serum calcium levels. However, more than 60% of patients achieved a greater than 30% decrease in intact PTH level from baseline with long-term OCT treatment up to 1 year without an unphysiological increase in mean serum calcium levels. Long-term treatment also brought about a reduction in bone metabolic markers, including bone alkaline phosphatase, tartrate-resistant acid phosphatase, and bone gra-protein. These results suggest that although careful attention should be paid to the onset of hypercalcemia and oversuppression of PTH, OCT is one of the effective tools for the treatment of secondary hyperparathyroidism.
影响因子：
19.6
作者：
Denda, M;Finch, J;Slatopolsky, E
通讯作者：
Slatopolsky, E